Syngene International, the Bengaluru‑based global contract research, development, and manufacturing organisation (CRDMO), has extended its long‑standing strategic collaboration with Bristol Myers Squibb (BMS) until 2035, marking a significant deepening of a partnership that began in 1998 and spans more than 25 years.
The expanded agreement broadens the scope of integrated services provided by Syngene across the entire drug development lifecycle — from early discovery through to clinical support and commercialisation — reinforcing Syngene’s role as a strategic scientific partner to BMS.
Under the renewed arrangement, Syngene will deliver a comprehensive suite of capabilities, including discovery research in chemistry and biology, drug metabolism and pharmacokinetics, translational sciences, pharmaceutical development and manufacturing, clinical trials support, and advanced data and information technology services.
This end‑to‑end support framework is designed to enable seamless progression of therapeutic programmes from initial concept to market readiness, strengthening operational integration between the two organisations.
Central to the collaboration is the Biocon Bristol Myers Squibb Research and Development Center (BBRC) in Bangalore, which was first commissioned in 2009 following the initial phases of the partnership. The BBRC has evolved into a major strategic R&D hub for BMS outside the United States, housing around 700 Syngene scientists who work as an extension of BMS’s global research organisation.
The centre supports integrated capabilities across key scientific functions such as target identification, lead discovery and optimisation, molecular and cell biology, protein sciences, assay biology, clinical biomarkers and early‑stage pharmaceutical development in multiple therapeutic areas including cardiovascular disease, fibrosis, immunology and oncology.
The collaboration’s longevity and expansion reflect sustained mutual investment in scientific infrastructure and talent, with the BBRC contributing to accelerated transitions from discovery to pre‑clinical development, as well as supporting patent filings and early‑stage research programmes.
By reinforcing this alliance through 2035, Syngene and Bristol Myers Squibb aim to maintain continuity in research momentum, enhance integrated scientific delivery, and support the development of innovative therapies at scale.
